clinical trial · NCT03329196
Efficacy and Safety Study to Evaluate MT-6548 in Non-dialysis Subjects With Anemia Associated With Chronic Kidney Disease in Japan
Anemia; Non-dialysis Dependent Chronic Kidney DiseaseMT-6548Darbepoetin alfa
brief summary
For Non-dialysis subjects with anemia associated with chronic kidney disease, demonstrate non-inferiority of MT-6548 compared to darbepoetin alfa using Hb value and evaluate long-term safety of MT-6548. For subjects not currently receiving ESAs, evaluate Hb correction and maintenance effect of MT-6548 and for subjects currently receiving ESAs, evaluate Hb conversion and maintenance effect of MT-6548
started
Oct 30, 2017
primary completion
Jan 8, 2019
completion
Aug 9, 2019
last updated
Apr 6, 2026
official title
A Phase III, Open-label, Confirmatory Study of MT-6548 Compared to Darbepoetin Alfa in Non-dialysis Subjects With Anemia Associated With Chronic Kidney Disease in Japan
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol